San Francisco, California (PRWEB) June 05, 2014

The global market for molecular diagnostics is expected to reach USD 8,020.1 million by 2020, according to a new study by Grand View Research, Inc. Growing demand for personalized medicine and theranostics, and the subsequent introduction of advanced cancer diagnostic technologies are expected to be key factors driving market growth over the next six years. Moreover, the growing global base of geriatric population and chronic diseases such as cancer, coupled with disease triggering lifestyle habits such as smoking and excessive alcohol consumption will positively impact market growth.

Molecular diagnostic reagent products dominated the overall market, accounting for over 50% of global revenue in 2013. Reagent market revenue is expected to reach USD 4,739.9 million by 2020, growing at a CAGR of 9.9% from 2014 to 2020. High consumption rates of molecular diagnostic reagents and the growing number of research and development initiatives pertaining to the field of molecular diagnostics are two key drivers of this product segment. The point of care end-use market for molecular diagnostics is expected to be the fastest growing product segment, at an estimated CAGR of 13.3% from 2014 to 2020, on account of factors such as the growing demand for point of care diagnostic procedures as an effective diagnostic tool rendering rapid and accurate results and the introduction of government initiatives such as CLIA (Clinical Laboratory Improvement Amendments) waived tests.

The report Molecular Diagnostics Market Analysis By Product (Instruments, Reagents), By Technology (PCR, In Situ Hybridization, Chips & Microarrays, Mass Spectrometry, Sequencing), By Application (Oncology, Pharmacogenomics, Infectious Disease, Genetic Testing, Neurological Disease, Cardiovascular Disease) And Segment Forecasts to 2020, is available now to Grand View Research customers at http://www.grandviewresearch.com/industry-analysis/molecular-diagnostics-market.

Request Free Sample of This Report at http://www.grandviewresearch.com/industry-analysis/molecular-diagnostics-market/request.

Further key findings from the study suggest:

Browse All Biotechnology Market Reports Available at Grand View Research at http://www.grandviewresearch.com/industry/biotechnology.

For the purpose of this study, Grand View Research has segmented the global molecular diagnostics market on the basis of product and region:

Browse Grand View Research Ongoing Reports at http://www.grandviewresearch.com/ongoing-reports.

Latest Report By Grand View Research:

Read the rest here:
Global Molecular Diagnostics Market By Product (Instruments, Reagents) By Technology (PCR, Sequencing) to Reach USD 8 ...

Recommendation and review posted by Bethany Smith

Medical Video Lecture: Chromosomal Deletion, Biochemistry ( genetics)
Prepare for USMLE,UK,CANADIAN,AUSTRALIAN, NURSING OTHER MEDICAL BOARD examinations around the globe with us. Understand the basics, concepts and how to answer wisely and score 99 in each...

By: allornonelaw

See the original post:
Medical Video Lecture: Chromosomal Deletion, Biochemistry ( genetics) - Video

Recommendation and review posted by Bethany Smith

The Sims 3 Perfect Genetics Episode 1 Welcome
Goodbye Persona 3 Hello Perfect Genetics. Hope You Enjoy This Episode Music By Kevin Macleod Pamgaea.

By: VanillaPlumbob

Read more:
The Sims 3 Perfect Genetics Episode 1 Welcome - Video

Recommendation and review posted by Bethany Smith

Promise of Discovery Personalized Medicine for Lung Cancer YouTube

By: Lee Thomas

Continue reading here:
Promise of Discovery Personalized Medicine for Lung Cancer YouTube - Video

Recommendation and review posted by sam

The Big Data Trend
Eliot Siegel, M.D., professor and vice chairman of radiology at the University of Maryland, School of Medicine, department of radiology, discusses the big data trend, and what it means to personali...

By: Imaging Technology News

The rest is here:
The Big Data Trend - Video

Recommendation and review posted by sam

Keeping Your Teens #39; Prom Night Safe
Keeping Your Teens Prom Night Safe We are happy to review any Connecticut case for matters involving Personal Injury or Medical Malpractice. We will review the following types of cases: All...

By: HCWLawCT

More here:
Keeping Your Teens' Prom Night Safe - Video

Recommendation and review posted by sam

What is Spinal Cord Injury?
This video scribe, designed by Deirdre Griffin of Spinal Injuries Ireland, uses simple language and images to explain what a spinal cord injury is.

By: Spinal Injuries

Follow this link:
What is Spinal Cord Injury? - Video

Recommendation and review posted by sam

Texting and Driving - Intern Series
Texting and Driving - Intern Series 3 Tips to Keep You Safe on the Roads We are happy to review any Connecticut case for matters involving Personal Injury or Medical Malpractice. We will...

By: HCWLawCT

View post:
Texting and Driving - Intern Series - Video

Recommendation and review posted by sam

Rheumatoid Arthritis

Currently, RA is treated with immune suppressive agents such as steroids, methothrexate, cyclosporine, gold, and more recently infliximab (Remicade). Despite inducing temporary improvement, these approaches possess long-term adverse effects due to non-specific inhibition of immune responses. Additionally, current treatments do not address the issue of damage that has already occurred to the joints or extra-articular tissues.

Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response.

Stem cell therapy has been demonstrated to induce profound healing activity in animals with various forms of arthritis. For example, the company Vet-Stem routinely utilizes stem cells in horses with various joint deformities to accelerate healing. Besides healing of damaged tissues, stem cells have the unique ability to modulate the immune system so as to shut off pathological responses while preserving ability to fight off disease. Stem cells and specifically, mesenchymal stem cells home to inflamed tissue and start producing anti-inflammatory agents. These mediators act locally and do not suppress the immune response of the patients whole body. Additionally, mesenchymal stem cells induce the production of T regulatory cells, a type of immune cell whose function is to protect the body against immunological self-attack.

The Stem Cell Institute uses adult stem cells called allogeneic mesenchymal stem cells to treat rheumatoid arthritis. These cells are harvested from human umbilical cords donated after normal, healthy births. All mothers who donate umbilical cords undergo infectious disease testing and medical history screening. Proper written consent is obtained from each family prior to umbilical cord donation.

All mesenchymal stem cells harvested from umbilical cords are screened for infectious diseases to International Blood Bank Standards before they are cleared for use in treatments.

Only about one in ten umbilical cords pass our rigorous screening process.

The bodys immune system is unable to recognize human umbilical cord tissue (HUCT)-derived mesenchmyal stem cells as foreign and therefore they are not rejected. HUCT stem cells have been administered thousands of times at the Stem Cell Institute and there has never been a single instance rejection (graft vs. host disease). Umbilical cord-derived mesenchymal stem cells also proliferate/differentiate more efficiently than older cells, such as those found in the fat and therefore, they are considered to be more potent.

Read the original post:
Stem Cell Therapy || Rheumatoid Arthritis Treatment ...

Recommendation and review posted by simmons

Contact Information

Available for logged-in reporters only

Newswise New York, New York Research to Prevent Blindness (RPB), the leading eye research foundation, is providing $500,000 to accelerate the development of treatments for Retinitis Pigmentosa (RP) -- a family of retinal diseases that progressively create extreme tunnel vision, loss of night vision and leave affected patients legally blind by the age of 40. The funds are being awarded to five nationally prominent RP investigators.

"Recent breakthroughs in gene therapy that reverse vision loss in certain RP patients have given us all hope that treatments for other forms of RP are within reach," says Diane S. Swift, Chair of RPBs Board of Trustees. While we have funded RP research for decades, the restoration of sight in these young people is so dramatic, and the developments in gene therapy so promising, that we felt focused investments in key RP researchers at this crucial time could hasten life-changing treatments."

The five recipients of the RPB Nelson Trust Award for Retinitis Pigmentosa were selected after rigorous review by multiple RPB advisory panels comprised of outstanding scientists and chairs of departments of ophthalmology from across the country. The award was originally conceived to produce at least one grant annually for the next eight to nine years, says Brian F. Hofland, PhD, RPB President, but we realized that the exceptional pool of applicants truly some of the nation's foremost retina investigators created an opportunity for us to make an immediate impact. It's an unusual application of endowed funds for us, but we are seizing the moment to push this promising science toward the goal."

Each of the RPB Nelson Trust Award awardees will receive $100K in flexible support to pursue novel projects.

Vadim Arshavsky, PhD, Duke University has made seminal discoveries related to the process by which light is converted into electrical signals in the photosensitive cells of the retina. He will focus on a newly discovered common risk factor for RP and the development of a possible treatment for multiple forms of RP that arise from different mutations. (Visit the Arshavsky Lab.) (More about Dr. Arshavsky.)

Wolfgang Baehr, PhD, University of Utah is frequently described as the leading retinal biochemist and molecular biologist of our era. His multifaceted studies will apply cutting edge genetic tools to address broad mechanisms shared by many forms of RP, creating new models for therapeutic study and developing new treatments. (Visit the Baehr Lab.) (More about Dr. Baehr.)

David M. Gamm, MD, PhD, University of Wisconsin is one of the undisputed leaders in stem cell research relevant to age-related macular degeneration. He intends to develop a rod-replacement-therapy for RP using human induced pluripotent stem cells, which can be created from a patients own skin cells. (More on Dr. Gamm and stem cell research video.)

Eric A. Pierce, MD, PhD, Harvard University is one of the leading investigators in RP research and has recently identified a possible genetic cause of RP. Dr. Pierces studies will provide a path to developing a gene therapy for diseases caused by mutations in this gene. (Visit the Pierce lab.)

See original here:
Top Retinitis Pigmentosa Scientists Earn Awards for Further Research

Recommendation and review posted by Bethany Smith

WELLESLEY, Mass., June 4, 2014 /PRNewswire-USNewswire/ --Is there an entrepreneurial gene? How does family affect female entrepreneurs? How are entrepreneurs resourceful?

The Ivey Business School of Western University is hosting the 34th annual Babson College Entrepreneurship Research Conference (BCERC) from June 4-7, 2014, in London, Ontario. Answers to these questions and more will be revealed at the Conference.

The Conference is widely considered the world's premier conference for entrepreneurship research which provides a dynamic venue for academics to link theory and practice. The event rotates annually among top business schools throughout Europe and North America, attracting over 400 of the world's leading academics who share the latest research findings about entrepreneurship.

There will be 237 presentations from academics from all around the world. The research to be presented at this year's conference will touch on many of the most important and pressing issues facing entrepreneurs in the 21st century. Examples of the topics covered will include the influence of household and family commitments on female entrepreneurs; the existence and impact of an "entrepreneurial gene"; and the ways entrepreneurs use their resourcefulness to create lasting value.

In addition to the Conference, Babson and Ivey will hold the 2014 BCERC Doctoral Consortium Program. The Doctoral Consortium provides 26 doctoral students from around the world with the opportunity to gain insight into current research issues through intense interaction with consortium faculty. This venue supports scholars and educators to become leaders in the field of entrepreneurship education.

On Friday evening, June 6, The National Federation of Independent Business (NFIB), the Stevens Institute of Technology, G. Dale Meyer and the Journal of Small Business Management, will present the Best Paper Awards for the 2013 issue of Frontiers of Entrepreneurship Research. Frontiers of Entrepreneurship Research contains the proceedings of the conference and is the most comprehensive collection of current empirical research papers on entrepreneurship, representing institutions from around the globe. For information, visit http://bit.ly/1neFXsT.

About the Ivey Business School, Western University

The Ivey Business School at Western University is Canada's leading provider of relevant, innovative and comprehensive business education. Drawing on extensive research and business experience, Ivey faculty provide the best classroom experience, equipping graduates with the skills and capabilities they need to tackle the leadership challenges in today's complex business world. Ivey offers world-renowned undergraduate and graduate degree programs as well as Executive Development at campuses in London (Ontario), Toronto and Hong Kong.

About Babson College

Babson College is the educator, convener, and thought leader for Entrepreneurship of All Kinds(tm). The College is a dynamic living and learning laboratory, where students, faculty, and staff work together to address the real-world problems of business and society--while at the same time evolving our methods and advancing our programs. We shape the leaders our world needs most: those with strong functional knowledge and the skills and vision to navigate change, accommodate ambiguity, surmount complexity, and motivate teams in a common purpose to create economic and social value. As we have for nearly a half-century, Babson continues to advance Entrepreneurial Thought and Action(r) as the most positive force on the planet for generating sustainable economic and social value. Visit http://www.babson.edu.

More here:
World's Top Entrepreneurial Minds To Gather At Ivey Business School To Share Latest Research At Babson College ...

Recommendation and review posted by Bethany Smith

They look like snakes, but don't be fooled: Legless, slithering amphisbaenians are more closely related to lizards than to boa constrictors.

Now, the first complete skull of the ancestor of today's bizarre "worm lizards" reveals that these strange reptiles have been largely unchanged for at least 11 million years. The fossil skull, discovered in Spain, is only 0.44 inches (11.2 millimeters long), but represents a new species, Blanus mendezi.

This family, known as blanids, includes the only worm lizards found on land in Europe, said study researcher Arnau Bolet, a doctoral student at the Institut Catal de Paleontologia Miquel Crusafont in Barcelona.

"Their fossil record was until now limited to isolated and usually fragmented bones," Bolet told Live Science in an email. "Thus, the study of a complete fossil skull more than 11 million years old was an unprecedented opportunity." [The 12 Weirdest Animal Discoveries]

Lizards without legs

Worm lizards are found around the world today, though most of the 180 or so extant species live in the Arabian Peninsula, Africa and South America. Some have rudimentary legs, but most have no limbs at all, and resemble large earthworms.

Today, there are three groups of worm lizards in the Mediterranean region: one group is eastern, one is Iberian and one is northwest African. The Iberian and northwest African groups probably arose from one western Mediterranean group that only later subdivided, Bolet and his colleagues explain today (June 4) in the journal PLOS ONE.

The new skull was found in sediments excavated in 2011 in the Valls-Peneds Basin in Spain's Catalonia region. Manel Mndez, a technician at the Institut Catal de Paleontologia Miquel Crusafont, was sifting through the dirt for fossils using a screen when he found a lumpy, pinkish rock that he knew was something more.

Continue reading here:
11-Million-Year-Old Weird Worm Lizard Discovered

Recommendation and review posted by Bethany Smith

The Indian cancer genetic research company MedGenome says it has taken $4 million in new funding to further develop and market its genetic sequencing research on cancer victims.

MedGenome licenses a bioinformatics database called OncoMD, which containsmore than 1.2 million cancer-related genetic mutations.

The funding round was led by Papillon Capitals Kartik Kumaramangalam and Emerge Ventures Mahesh Pratapneni and includes several other individual investors all data science executives.

MedGenome is already the leader in the Indian genomics market, says MedGenome CEO Sam Santhosh in a statement today. The new resources from this investment round will enable us to expand our research and make our tools more widely available to clinicians and hospitals developing personalized treatment strategies for cancer patients around the world.

Health informatics businesses dont lend themselves to 30-second elevator pitches very well. Heres the short version, as explained to VentureBeatby MedGenome investor Dmitri Mehlhorn.

In twins, who have very similar genes, its easy for genetic researchers to understand the small genetic differences that may have led to cancer in one twin but not in the other. Oncologists might be able to recognize that same genetic mutationin other people as a possible warning sign for cancer. But there are only so many twins to study.

So genetic researchers look for whole groups of people whose genetic make-ups are very similar. For instance, the populations of Utah and Iceland are genetically very homogeneous, and both of those groups have yielded a wealth of genetic lessons for medicine.

India, it turns out, has hundreds of genetically homogeneous castes, tribes, and ethnic groups. Its like having a hundred Icelands in one country, Mehlhorn told me.

MedGenomes database of genetic mutations can help physicians and hospitals pinpoint patients mutation hotspots, identify prevalent cancer types, flag potential sensitivity to therapies, and link mutations to open clinical trials, as MedGenome puts it.

Mehlhorn saysMedGenome is already profitable but needs the newfunding to bring its cancer data to more hospitals and research institutions.

Visit link:
Data scientists back MedGenomes database of genetic mutations for cancer research with $4M

Recommendation and review posted by Bethany Smith

The Sims 3: Perfect Baby Challenge - Part 4 | Strong Genetics.
Read The Description Please. Challenge Rules: 100 Baby Challenge: http://modthesims.info/t/465479 Perfect Genetics: http://modthesims.info/t/454886 S...

By: PlumbobAddict

See the original post here:
The Sims 3: Perfect Baby Challenge - Part 4 | Strong Genetics. - Video

Recommendation and review posted by Bethany Smith

Lets Play The Sims 3 Perfect Genetics Part 4: Dirty Girl!
Watch as we get a better look into Marina #39;s life before us! My Sims 3 Page: http://mypage.thesims3.com/mypage/becky050890 My Husband #39;s Sims 3 Page: http://mypage.thesims3.com/mypage/gordonwisner2...

By: GBabyChallenger

Here is the original post:
Lets Play The Sims 3 Perfect Genetics Part 4: Dirty Girl! - Video

Recommendation and review posted by Bethany Smith

Q A Part 5 Muscle Increase In Metabolism Training When Sore Average Genetics Stubborn Fat
0:15 Jason, about how much does a pound of muscle raise your BMR/TDEE? I #39;ve heard its between 7-15 calories per pound of muscle, is that pretty accurate? If ...

By: JuggernautFitnessTV

See original here:
Q&A Part 5 Muscle Increase In Metabolism Training When Sore Average Genetics Stubborn Fat - Video

Recommendation and review posted by Bethany Smith

EOC Review for Genetics Part I
EOC Review for Genetics Part I.

By: Marajo Kellihan

Read more:
EOC Review for Genetics Part I - Video

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

4-Jun-2014

Contact: Karen Kreeger karen.kreeger@uphs.upenn.edu 215-349-5658 University of Pennsylvania School of Medicine

PHILADELPHIA Advances in the understanding of the genetics of coronary artery disease, or CAD, will revitalize the field and lead to more therapeutic targets for new medicines to combat this common disease, suggests a genetics expert from the Perelman School of Medicine at the University of Pennsylvania in a Perspective article in the new issue of Science Translational Medicine.

Daniel J. Rader, MD, chair of the Department of Genetics and associate director of the Institute for Translational Medicine and Therapeutics, asserts that the lagging search for new heart medicines could be jump-started by a wide-angle hunt for relevant genetic variants in humans.

According the America Heart Association, the death rate from heart disease has fallen about 39 percent during the past 10-most-recent years for which statistics are available. Still, heart disease is the number-one cause of death in the United States, killing almost 380,000 people a year.

Although progress has been made in decreasing the risk of heart disease, with the single greatest contribution made by statins to reduce levels of low-density lipoprotein cholesterol (LDL-C) in millions of people, the burden of the disease remains high. "Despite this clear unmet need, however, many biopharmaceutical companies have begun to back away from efforts to discover and develop therapies for this prevalent disease," writes Rader, citing seven drugs that have failed in phase 3 clinical trials in the last three to five years.

The single biggest issue facing the development of new therapeutics for heart disease is confidence before expensive human trials are underway that the target of a new drug has a high probability of success in reducing disease. Animal models of atherosclerosis, however, have not proven reliable at predicting new therapies that are effective in humans. In contrast, Rader says, basing drug targets on human genetics can provide greater confidence that a therapeutic targeted to a particular pathway will show clinical benefit in reducing major cardiovascular events in people. As with recent successes in cancer immunotherapy, a targeted, personalized approach to developing new treatments has proved attractive to big pharma.

Human genetic data strongly support the concept that reducing LDL-C by any means is associated with a lower cardiovascular risk. This association is consistent with LDL-C being a causal factor in the development of cardiovascular disease. Indeed, the discovery that mutations in the gene PCSK9 reduce LDL-C and protect against CAD launched a major effort to develop inhibitors of PCSK9, which markedly reduce LDL-C and are in late-stage clinical development.

Similar genetic data for triglycerides were recently published, suggesting that specific proteins regulating this blood chemical might be viable therapeutic targets. On the other hand, human genetic data provide little support for raising high-density lipoprotein cholesterol (HDL-C) because genetic variants associated with increased HDL-C are not generally associated with decreased cardiovascular risk.

Continue reading here:
Genetics provide blueprint for new heart disease therapies

Recommendation and review posted by Bethany Smith

Contact Information

Available for logged-in reporters only

Newswise PHILADELPHIA Advances in the understanding of the genetics of coronary artery disease, or CAD, will revitalize the field and lead to more therapeutic targets for new medicines to combat this common disease, suggests a genetics expert from the Perelman School of Medicine at the University of Pennsylvania in a Perspective article in the new issue of Science Translational Medicine.

Daniel J. Rader, MD, chair of the Department of Genetics and associate director of the Institute for Translational Medicine and Therapeutics, asserts that the lagging search for new heart medicines could be jump-started by a wide-angle hunt for relevant genetic variants in humans.

According the America Heart Association, the death rate from heart disease has fallen about 39 percent during the past 10-most-recent years for which statistics are available. Still, heart disease is the number-one cause of death in the United States, killing almost 380,000 people a year.

Although progress has been made in decreasing the risk of heart disease, with the single greatest contribution made by statins to reduce levels of low-density lipoprotein cholesterol (LDL-C) in millions of people, the burden of the disease remains high. Despite this clear unmet need, however, many biopharmaceutical companies have begun to back away from efforts to discover and develop therapies for this prevalent disease, writes Rader, citing seven drugs that have failed in phase 3 clinical trials in the last three to five years.

The single biggest issue facing the development of new therapeutics for heart disease is confidence before expensive human trials are underway that the target of a new drug has a high probability of success in reducing disease. Animal models of atherosclerosis, however, have not proven reliable at predicting new therapies that are effective in humans. In contrast, Rader says, basing drug targets on human genetics can provide greater confidence that a therapeutic targeted to a particular pathway will show clinical benefit in reducing major cardiovascular events in people. As with recent successes in cancer immunotherapy, a targeted, personalized approach to developing new treatments has proved attractive to big pharma.

Human genetic data strongly support the concept that reducing LDL-C by any means is associated with a lower cardiovascular risk. This association is consistent with LDL-C being a causal factor in the development of cardiovascular disease. Indeed, the discovery that mutations in the gene PCSK9 reduce LDL-C and protect against CAD launched a major effort to develop inhibitors of PCSK9, which markedly reduce LDL-C and are in late-stage clinical development.

Similar genetic data for triglycerides were recently published, suggesting that specific proteins regulating this blood chemical might be viable therapeutic targets. On the other hand, human genetic data provide little support for raising high-density lipoprotein cholesterol (HDL-C) because genetic variants associated with increased HDL-C are not generally associated with decreased cardiovascular risk.

Although circulating biomarkers such as LDLs and triglycerides, commonly measured in standard blood lipid panels, are useful for guiding drug development programs focused on reducing CAD, Rader contends that many of the genetically validated targets for CAD will not have well-established circuiting biomarkers. Some of the most interesting new targets for atherosclerotic cardiovascular disease are likely to come from genetic studies of common and rare variants, comparing individuals with early disease with those who are free of disease, says Rader.

Read more:
Genetics Provide Blueprint for New Heart Disease Therapies, Writes Penn Medicine Researcher

Recommendation and review posted by Bethany Smith

gene therapy,also called gene transfer therapy, introduction of a normal gene into an individuals genome in order to repair a mutation that causes a genetic disease. When a normal gene is inserted into the nucleus of a mutant cell, the gene most likely will integrate into a chromosomal site different from the defective allele; although this may repair the mutation, a new mutation may result if the normal gene integrates into another functional gene. If the normal gene replaces the mutant allele, there is a chance that the transformed cells will proliferate and produce enough normal gene product for the entire body to be restored to the undiseased phenotype.

Human gene therapy has been attempted on somatic (body) cells for diseases such as cystic fibrosis, adenosine deaminase deficiency, familial hypercholesterolemia, cancer, and severe combined immunodeficiency (SCID) syndrome. Somatic cells cured by gene therapy may reverse the symptoms of disease in the treated individual, but the modification is not passed on to the next generation. Germinal gene therapy aims to place corrected cells inside the germ line (e.g., cells of the ovary or testis). If this is achieved, these cells will undergo meiosis and provide ... (200 of 506 words)

Read this article:
gene therapy (medicine) -- Encyclopedia Britannica

Recommendation and review posted by Bethany Smith

MIAMI (PRWEB) June 04, 2014

GlobalStemCellsGroup.com, its subsidiary Stem Cell Training, Inc. and Bioheart, Inc. have announced a new 16 CME online credit course for physicians. Working at their own pace from the privacy of home or office, physicians can learn how to implement regenerative medicine techniques in their own practices.

Taught by stem cell and regenerative medicine expert Kristin Comella, the online course provides didactic lectures on regenerative medicine and scientifically validated protocols. Lecture topics include:

Included in the online coursework are training videos, training booklets, detailed protocols and power point presentations with instructions and images for:

Medical professionals can also choose to combine the online coursework with one-on-one training with a regenerative medicine specialist.

For more information, visit the Global Stem Cells website,, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

Go here to see the original:
Global Stem Cells Group Announces Accredited Online Stem Cell Training Course

Recommendation and review posted by simmons

Arthritic hip, knee, and thumbs 9 months after stem cell therapy by Dr Harry Adelson
Raymond and Nina describe their outcomes from stem cell therapy by Dr Harry Adelson for their various arthritic pains http://www.docereclinics.com.

By: Harry Adelson, N.D.

See the rest here:
Arthritic hip, knee, and thumbs 9 months after stem cell therapy by Dr Harry Adelson - Video

Recommendation and review posted by simmons

New York, NY (PRWEB) June 04, 2014

The Animal Medical Center of New York is offering stem cell therapy provided through Vet-Stem and long-term management in a clinical trial for qualifying cats with chronic kidney disease (CKD). The ultimate goal of this study is to investigate the use of stem cells (obtained from the patients own fat) in aiding the enhancement of renal (kidney) function by their regenerative capabilities, with the goal of improving survival in cats with CKD.

Currently there are no therapeutic options for cats with CKD other than renal transplantation, which is not typically an option for most owners. Most efforts aim at improving uremic signs with food, dietary supplements, and antacids, but there are no current methods for improving function of the kidney directly. CKD is the leading cause of death in older cats, and 35% of cats will develop CKD at some point.

Since renal failure is so common in cats and renal cell death is the ultimate result, improving the health and environment of the cells that remain could improve the overall function of the kidneys and ultimately improve the survival times and quality of life in patients. The aim is to use the cats own adipose (fat) derived stem cells to improve renal function directly, as stem cells are thought to improve, repair, and aid in the growth of damaged tissue.

The potential health benefits of using stem cells to combat CKD include renal regeneration, anti-fibrotic effects, a decrease in proteinuria (also called urine albumin or an abnormal amount of protein in the urine), and an improvement in the Glomerular Filtration Rate (GFR used to help measure kidney function). AMC is offering free fat collection, isolation of the stem cells from the fat, and intra-arterial injection for qualifying cats, as well as free follow-up for three years. Qualifying cats must be diagnosed with IRIS Stage 3 CKD that have had no other experimental therapies. Potential candidates must undergo a full workup and have no history of urinary tract stone disease or the presence of other concurrent, unrelated disease.

Allyson Berent, DVM, DACVIM and Catherine E. Langston, DVM, DACVIM will be leading the three year study, and invite owners with a cat that has been diagnosed with CKD to call 212.329.8763 for more information on qualifying for the clinic trial. To learn more about the study go to http://www.amcny.org/clinicaltrials. To watch a short special interest film about one cats success go to http://www.vet-stem.com/pr_detail.php?id=49.

The Animal Medical Center in New York City is a federally recognized 501(c)(3) non-profit veterinary center that has been a national leader in animal care since 1910. As an academic veterinary hospital, The AMC promotes the health and well-being of companion animals through advanced treatment, research and education. Stem Cell Therapy through Vet-Stem has been offered at AMC since 2008 to treat pain associated with chronic osteoarthritis. To find out more about AMC and their stem cell therapy services for osteoarthritis go to http://www.amcny.org/surgery/neurosurgery/stem-cell-therapy.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Read this article:
Animal Medical Center of New York Seeks Candidates for Clinical Trial for Cats with Chronic Kidney Disease to Receive ...

Recommendation and review posted by simmons

A NEW method of helping bone marrow stem cells "mature" is pushing science closer to being able to treat brain injuries by creating specific cells capable of repairing damaged areas.

By modifying the surface of these cells and ensuring the proper environment, these otherwise easy-to-obtain marrow cells could drive brain regeneration.

Although this is only a small step forward, the hope is that these techniques could one day help treat those who have suffered brain damage, including those resulting from a stroke.

Nationally, there are 420,000 Australians living with the effects of stroke in Australia.

There are about 50,000 new and recurrent strokes each year, about 29,000 of those in Queensland and New South Wales.

National Stroke Foundation spokeswoman Professor Richard Linley said the research had the potential to help stroke patients, but was clearly in the very early stages of development.

Queensland University of Technology researcher Rachel Okolicsanyi said while the capability of these marrow stem cells has been understood for some time, this research into influencing how they mature could create techniques to convert them into brain or neural cells.

Ms Okolicsanyi, with supervisors Dr Larisa Haupt and Professor Lyn Griffiths , will now attempt to nail down a technique that will deliver routine results.

Ms Okolicsanyi's work was published in the journal Developmental Biology.

Read more here:
New stem cell methods may help brain injuries

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

3-Jun-2014

Contact: Sandra Hutchinson s3.hutchinson@qut.edu.au 61-731-389-449 Queensland University of Technology

A QUT scientist is hoping to unlock the potential of stem cells as a way of repairing neural damage to the brain.

Rachel Okolicsanyi, from the Genomics Research Centre at QUT's Institute of Health and Biomedical Innovation, said unlike other cells in the body which were able to divide and replicate, once most types of brain cells died, the damage was deemed irreversible.

Ms Okolicsanyi is manipulating adult stem cells from bone marrow to produce a population of cells that can be used to treat brain damage.

"My research is a step in proving that stem cells taken from the bone marrow can be manipulated into neural cells, or precursor cells that have the potential to replace, repair or treat brain damage," she said.

Ms Okolicsanyi's research has been published in Developmental Biology journal, and outlines the potential stem cells have for brain damage repair.

"What I am looking at is whether or not stem cells from the bone marrow have the potential to differentiate or mature into neural cells," she said.

"Neural cells are those cells from the brain that make everything from the structure of the brain itself, to all the connections that make movement, voice, hearing and sight possible."

View post:
Unlocking the potential of stem cells to repair brain damage

Recommendation and review posted by Bethany Smith